United Therapeutics Corp

NASDAQ:UTHRUnited States

By Don Nico Forbes

Liquidia said a U.S. court determined losses caused by interference from United Therapeutics during the launch of its generic Treprostinil Injection were in excess of $137 million.

Report available at corporateresponsibility.unither.com
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--September 10, 2024--
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation (PBC), today announced the release of its 2024 Corporate Responsibility and Public Benefit Report (Report) covering its FY 2023 progress toward its public benefit goals and objectives and summarizing its efforts to advance the interests of patients and other stakeholders.

04:57 PM EDT, 09/04/2024 (MT Newswires) -- James Edgemond, CFO and Treasurer, on September 03, 2024, sold 7,785 shares in United Therapeutics (UTHR) for $2,821,050. Following the Form 4 filing with the SEC, Edgemond has control over a total of 3,162...